23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function

23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function

Immune checkpoint inhibition (ICI) has revolutionized cancer treatment; however, only a subset of patients benefit long term. Therefore, methods for identification of novel checkpoint targets and development of therapeutic interventions against them remain a critical challenge. Analysis of human gen...

Full description

Bibliographic Details
Main Authors: Jill Fenaux, Xin Fang, Yao-ming Huang, Cristina Melero, Caroline Bonnans, Earth Light Lowe, Tiziana Palumbo, Cecilia Lay, Zuoan Yi, Aileen Zhou, Mauro Poggio, Wei-Jen Chung, Sophia R. Majeed, Dylan Glatt, Alice Chen, Maike Schmidt, Clarissa C. Lee
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
23ME-00610
cancer immunotherapy
CD200
CD200R1
immune checkpoint
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2217737

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2217737

Similar Items